MitoTEMPOL
Based on 4 publication(s) in Google Scholar
MitoTEMPOL is a mitochondria-targeted superoxide scavenger. MitoTEMPOL accumulates in mitochondria via membrane potential and locally scavenges superoxide anions. MitoTEMPOL alleviates hepatic oxidative stress and alterations in genes related to autophagy in STZ (HY-13753)-induced diabetic models. MitoTEMPOL inhibits diaphragmatic mitochondrial dysfunction and activation of proteolytic pathways in sepsis models. MitoTEMPOL also alleviates AGEs (HY-NP165)-induced ferritinophagy-dependent ferroptosis in human umbilical vein endothelial cells. MitoTEMPOL is used in research related to diabetes, sepsis, and vascular endothelial ferroptosis.
For research use only. We do not sell to patients.
- Purity : 99.9%
- CAS No.: 1101113-39-6
- Formula: C32H42BrNO2P*
- Molecular Weight:583.56
-
Storage:
-20°C, sealed storage, away from moisture and light, under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) MitoTEMPOL
More
Biological Activity
Description
In Vitro
MitoTEMPOL (10 mg/l; 24 h) eliminates cytokine-induced superoxide production in C2C12 myocytes[2].
MitoTEMPOL (pretreatment for 1 h) scavenges ROS and alleviates AGEs (HY-NP165)-induced ferroptosis and ferritinophagy in HUVECs[3].
MitoTEMPOL (10 mg/l; 24 h) prevents cytokine-induced reduction in C2C12 myotube width[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MitoTEMPOL (10 mg/kg; i.p.; administered twice, after surgery and 24 h later) prevents sepsis-induced diaphragmatic weakness, mitochondrial dysfunction, proteolytic enzyme activation, and myosin heavy chain loss[2].
MitoTEMPOL (10 mg/kg; i.p.; administered immediately after surgery or with the first injection delayed until 6 h post-surgery (followed by a second injection 24 h later)) is as effective as immediate injection in preventing sepsis-induced diaphragm weakness[2].
MitoTEMPOL (10 mg/kg; i.p.; administered at the time of CLP induction) blocks the early decrease in aconitase activity and prevents the late activation of proteases in the septic diaphragm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (Male, 8 weeks old, 210 g, STZ-induced diabetes)[1]
-
Dosage:100 mg/kg BW/day
-
Administration:p.o.; 5 times a week; 5 weeks
-
Result:Reduced lipid droplets in both this compound-only and STZ + this compound groups compared to control and STZ groups.
Increased Parkin gene expression 1.22-fold in this compound-only group and 1.22-fold in STZ + this compound group compared with control.
Increased BNIP3 gene expression 1.28-fold in this compound-only group compared with control.
Increased BNIP3 gene expression 1.26-fold in STZ + this compound group compared with STZ and 1.32-fold compared with control.
Increased Mfn1 gene expression 1.36-fold in this compound-only group compared with control and 1.21-fold compared with STZ group.
Increased Mfn1 gene expression 1.26-fold in STZ + this compound group compared with STZ and 1.23-fold compared with control.
Increased LC3 gene expression 1.26-fold in this compound-only group compared with control and 1.29-fold compared with STZ group.
Increased LC3 gene expression 1.24-fold in STZ + this compound group compared with STZ group.
-
Animal Model:ICR (CD-1) (Male, 25-30 g, Cecal ligation puncture (CLP) induced sepsis)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; after surgery and again at 24 hours
-
Result:Blocked the sepsis-induced reduction in diaphragm strength, with force at 50 Hz averaging 27.0 N/cm2 for CLP + this compound versus 12.6 N/cm2 for CLP.
Maintained diaphragm force at the end of repetitive contraction trials at 12.6 versus 4.0 for CLP.
Prevented CLP-induced reductions in mitochondrial function, increasing state 3 oxygen consumption, RCR, and ATP production rates to levels significantly higher than for CLP septic animals.
Completely prevented CLP-induced increases in diaphragm calpain activity (355% increase in CLP), caspase 3 activity (352% increase in CLP), and 20S proteasome activity (226% increase in CLP).
Prevented the sepsis-induced reduction in diaphragm myosin heavy chain levels.
-
Animal Model:ICR (CD-1) (Male, 25-30 g, Cecal ligation puncture (CLP) induced sepsis)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; at 6 hours after surgery and again at 24 hours after surgery
-
Result:Prevented sepsis-induced loss of diaphragm strength, with diaphragm specific force generation for CLP + delayed this compound groups significantly higher than levels for the CLP group.
Showed similar findings for force measurements during repetitive contraction trials, with force at every time point similar for delayed and immediate this compound groups, and both significantly higher than CLP animals.
-
Animal Model:ICR (CD-1) (Male, 25-30 g, Cecal ligation puncture (CLP) induced sepsis)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; at the time of induction of CLP
-
Result:Blocked early reductions in aconitase activity at all time points and prevented proteolytic enzyme activation at 24 hours.
Had higher aconitase levels at all time points after CLP as compared to saline treated CLP groups.
Reduced all three proteolytic enzyme activities at the 24 hour time point for caspase, calpain and 20S proteasome activities.
- LPS-Induced Endotoxemia/Systemic Inflammation
- ROS/oxidative-stress fluorescent staining
- Fluorescent plasma-membrane potential dye assay
- Autophagy
- Mitochondrial membrane-potential and mitochondrial mass staining
- Endothelial Tube Formation Assay
- Lysosome and acidic-vesicle live-cell staining
- Ferroptosis Solutions
- Macroautophagy Solutions
- Research Protocol for Metabolic Diseases
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1101113-39-6
-
Appearance Solid
-
Molecular Weight 583.56
-
Formula C32H42BrNO2P*
-
Color Brown to orange
-
SMILES
[O]N1C(C)(CC(CC1(C)C)OCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)C.[Br-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light, under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Redox Biol
Advanced glycation end-products exacerbate myocardial ischemia/reperfusion injury by promoting mitochondrial oxidative damage and PANoptosis in diabetes mellitus. [Abstract]2026 Jul:94:104228. PMID: 42176503 -
Cell Rep Med
Vorapaxar enhanced mitochondria-associated ferroptosis primes cancer immunotherapy via targeting FOXO1/HMOX1 axis. [Abstract]2025 Sep 25:102371. PMID: 41005298 -
Int J Dent
The ROS/CaMK II/β-Catenin Signaling Axis Affects the Osteogenic Potential of BMSCs and Disrupts Implant Osseointegration: An In Vitro Study. [Abstract]2025 Aug 15:2025:5566776. PMID: 40861924 -
bioRxiv
2025 Nov 13:2025.11.11.687895. PMID: 41292779
Solvent & Solubility
In Vitro:
DMF : 50 mg/mL (85.68 mM; Need ultrasonic and warming)
Ethanol : 50 mg/mL (85.68 mM; Need ultrasonic and warming)
DMSO : 50 mg/mL (85.68 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / Ethanol / DMSO | 1 mM | 1.7136 mL | 8.5681 mL | 17.1362 mL | 42.8405 mL |
| 5 mM | 0.3427 mL | 1.7136 mL | 3.4272 mL | 8.5681 mL | |
| 10 mM | 0.1714 mL | 0.8568 mL | 1.7136 mL | 4.2840 mL | |
| 15 mM | 0.1142 mL | 0.5712 mL | 1.1424 mL | 2.8560 mL | |
| 20 mM | 0.0857 mL | 0.4284 mL | 0.8568 mL | 2.1420 mL | |
| 25 mM | 0.0685 mL | 0.3427 mL | 0.6854 mL | 1.7136 mL | |
| 30 mM | 0.0571 mL | 0.2856 mL | 0.5712 mL | 1.4280 mL | |
| 40 mM | 0.0428 mL | 0.2142 mL | 0.4284 mL | 1.0710 mL | |
| 50 mM | 0.0343 mL | 0.1714 mL | 0.3427 mL | 0.8568 mL | |
| 60 mM | 0.0286 mL | 0.1428 mL | 0.2856 mL | 0.7140 mL | |
| 80 mM | 0.0214 mL | 0.1071 mL | 0.2142 mL | 0.5355 mL |
MitoTEMPOL Related Classifications
HY-115386 Related Classifications
Powered by Bioz